Evidence map›Paper›PMID 38722319›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2024

Diagnostics of allergic rhinitis under dupilumab therapy.

Patrick Huber, Moritz Gröger, Clemens Stihl, Hanna Frankenberger, Mattis Bertlich, Frank Haubner, Donata Gellrich

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Food allergy clinical course in children and adolescents treated with dupilumab for atopic dermatitis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Patrick HuberDepartment of Oto-Rhino-Laryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Marchioninistraße 15, 81377, Munich, Germany. Patrick.Huber@med.uni-muenchen.de.ORCID http://orcid.org/0000-0001-6962-9999
Moritz GrögerDepartment of Oto-Rhino-Laryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Marchioninistraße 15, 81377, Munich, Germany.
Clemens StihlDepartment of Oto-Rhino-Laryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Marchioninistraße 15, 81377, Munich, Germany.
Hanna FrankenbergerDepartment of Oto-Rhino-Laryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Marchioninistraße 15, 81377, Munich, Germany.
Mattis BertlichDepartment of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany.
Frank HaubnerDepartment of Oto-Rhino-Laryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Marchioninistraße 15, 81377, Munich, Germany.
Donata GellrichDepartment of Oto-Rhino-Laryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Marchioninistraße 15, 81377, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAllergic rhinits is a prevalent condition, affecting a substantial proportion of the population. This study investigates the impact of ongoing biologic therapy, specifically with Dupilumab, on allergy diagnostics in patients with allergic rhinits.

methodsVarious tests, including the Skin Prick Test, serum IgE levels and Allergy Screening Panels, were examined for their effectiveness in detecting sensitizations during biologic treatment.

resultsThe results indicate a significant decline in total IgE levels following biologic therapy initiation, aligning with previous findings on Dupilumab's inhibitory effects on IL-4 and IL-13. However, the specific IgE to total IgE ratio for major allergens was not significantly reduced. Comparing diagnostic tools, the Skin Prick Test demonstrates an impressive retention rate of sensitizations (98%) during Dupilumab treatment, outperforming the Allergy Screening Panel, which shows a 75% detection rate. Notably, the panel displays limitations in capturing lower sensitization levels.

conclusionIn summary, this study underscores that, despite the influence of biologic therapy on certain markers, standard allergy tests remain viable while emphasizing the importance of considering specific IgE levels rather than relying solely on CAP classes. The Skin Prick Test in particular proves to be a reliable tool for identifying sensitizations during Dupilumab treatment. The results offer valuable guidance for the diagnostic management of Allergic rhinits in individuals subjected to Dupilumab treatment.

Indexed as

Antibodies, Monoclonal, HumanizedImmunoglobulin ERhinitis, AllergicSkin TestsAdultAgedFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizeddupilumabImmunoglobulin EAllergic rhinitisAllergy diagnosticsBiologicsChronic rhinosinusitisDupilumab

Identifiers

PMID38722319
PMCPMC11266438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.